Covagen

Via its patented Fynomer®-technoloy, Covagen, founded in 2007 as a spin-off company of ETH Zurich (Swiss), develops bispecific FynomAbs, proteins that have the ability to fuse to multiple sites on an antibody. This technology results in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. In August 2014, Covagen was acquired by Cilag GmbH International.

Icon entry

2013

Icon exit

2014

Icon location

Schweiz

Überblick

Aktivität
Development of bispecific FynomAbs
Land
Investitionsjahr
Plattform
Exit date
2014